1. Generics Bulletin
  2. >>Archive

New BGMA Chief Battles Twin Pressures Of COVID And Brexit

Product Withdrawals Have Already Begun In Northern Ireland, Says Mark Samuels

 
• By Dave Wallace

When Mark Samuels took over leadership of the BGMA earlier this year, he was immediately forced to grapple with the twin pressures of Brexit and the COVID-19 pandemic. However, he tells Generics Bulletin in an exclusive interview, the UK off-patent industry has succeeded in maintaining supply against this difficult backdrop and deserves a more coherent government strategy to support the sector.

COVID Brexit UK EU Map
Brexit and COVID-19 are putting a strain on the UK off-patent industry • Source: Alamy

When Mark Samuels took over as CEO of the British Generic Manufacturers Association in early 2021, it was something of a baptism of fire for the former Roche executive.

Forced to grapple with the combined pressures of the UK’s formal withdrawal from the EU medicines framework and the ongoing COVID-19 pandemic, the country’s off-patent industry has nevertheless managed to maintain supply and avoid shortages, he tells Generics Bulletin in an exclusive two-part

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Generics Bulletin

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.